IDEXX Laboratories Stock

IDEXX Laboratories Equity

The The Equity of IDEXX Laboratories (IDXX) as of Aug 25, 2026 is 1.61 B USD. In the previous year, The Equity was 1.60 B USD — a change of 0.63% (higher).

Equity

1.61 BUSD

YoY

0.63%

Last updated:

In 2026, IDEXX Laboratories's equity was 1.61 B USD, a 0.63% increase from the 1.60 B USD equity in the previous year.

The IDEXX Laboratories Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2018
-9.51 M USD
Jan 1, 2019
177.47 M USD
Jan 1, 2020
632.09 M USD
Jan 1, 2021
689.99 M USD
Jan 1, 2022
608.74 M USD
Jan 1, 2023
1.48 B USD
Jan 1, 2024
1.60 B USD
Jan 1, 2025
1.61 B USD
The IDEXX Laboratories Equity history
YEAREquityYoY
1.61 BUSD+0.63%
1.60 BUSD+7.46%
1.48 BUSD+143.87%
608.74 MUSD-11.78%
689.99 MUSD+9.16%
632.09 MUSD+256.16%
177.47 MUSD-1,965.58%
-9.51 MUSD-82.42%
-54.11 MUSD-50.06%
-108.35 MUSD+28.80%
-84.13 MUSD-171.59%
117.52 MUSD—
Access this data via the Eulerpool API
Get Free API Key

IDEXX Laboratories Stock analysis

What does IDEXX Laboratories do? The history of IDEXX Laboratories Inc began in 1983 when a research team from the University of Maine developed technology for the automatic analysis of animal blood. The first products were soon sold and the company grew rapidly. Today, IDEXX is a leading global provider of veterinary diagnostic and IT solutions, recognized by customers in over 175 countries. IDEXX's business model is based on innovation and a comprehensive understanding of the needs of veterinarians and their patients. The company offers a wide range of products and solutions that make the diagnosis and treatment of animal diseases easier and more reliable. These include tests and devices for blood analysis, urine and stool diagnostics, as well as imaging, infection control, and cancer diagnostics. The company has several divisions that focus on different aspects of veterinary diagnostics. IDEXX Diagnostics is the largest business segment, offering veterinary lab services, diagnostic tests, and software solutions. IDEXX Water is a company specializing in the analysis of water samples and monitoring of environmental conditions. IDEXX Livestock, the newest division of IDEXX, provides veterinary solutions for agricultural and livestock operations. Key products of IDEXX include tests for parasites, infections, diabetes, and kidney function. The company has also developed some innovative products, such as SNAP tests, which provide fast and accurate results and can perform tests for various pathogens simultaneously. IDEXX is also a company committed to sustainability. The IDEXX Foundation was established in 2013 and has since donated over $32 million to local and global projects that aim to protect animals and the environment. Overall, IDEXX Laboratories Inc is a company specialized in veterinary diagnostic and IT solutions to support veterinarians in treating animals. The wide range of solutions and products, as well as the commitment to sustainability, make the company an important player in the market for veterinary diagnostics. IDEXX Laboratories is one of the most popular companies on Eulerpool.

Equity Details

Analyzing IDEXX Laboratories's Equity

IDEXX Laboratories's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding IDEXX Laboratories's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating IDEXX Laboratories's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

IDEXX Laboratories's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in IDEXX Laboratories’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about IDEXX Laboratories stock

The Equity of IDEXX Laboratories is 1.61 B USD in 2026.

The Equity of IDEXX Laboratories changed from 1.60 B USD to 1.61 B USD, representing a 0.63% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Equity IDEXX Laboratories since 2006 – with annual values, charts, and detailed analysis.

The Equity's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's IDEXX Laboratories historically and in real time.

Access this data via the Eulerpool API
Get Free API Key

Balance Sheet — IDEXX Laboratories

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — IDEXX Laboratories